Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer

Dmitri Lodygin(Max Planck Institute of Biochemistry), Valery Tarasov(Max Planck Society), Alexey Epanchintsev(Max Planck Society), Carola Berking, Tatjana Knyazeva(Max Planck Society), Henrike Körner(Max Planck Society), Piotr G. Knyazev(Max Planck Society), Joachim Diebold, Heiko Hermeking
Cell Cycle
August 15, 2008
Cited by 783Open Access
Full Text

Abstract

Recently, we and others identified the microRNA miR-34a as a target of the tumor suppressor gene product p53. Ectopic miR-34a induces a G(1) cell cycle arrest, senescence and apoptosis. Here we report that miR-34a expression is silenced in several types of cancer due to aberrant CpG methylation of its promoter. 19 out of 24 (79.1%) primary prostate carcinomas displayed CpG methylation of the miR-34a promoter and concomitant loss of miR-34a expression. CpG methylation of the miR-34a promoter was also detected in breast (6/24; 25%), lung (7/24; 29.1%), colon (3/23; 13%), kidney (3/14; 21.4%), bladder (2/6; 33.3%) and pancreatic (3/19; 15.7%) carcinoma cell lines, as well as in melanoma cell lines (19/44; 43.2%) and primary melanoma (20/32 samples; 62.5%). Silencing of miR-34a was dominant over its transactivation by p53 after DNA damage. Re-expression of miR-34a in prostate and pancreas carcinoma cell lines induced senescence and cell cycle arrest at least in part by targeting CDK6. These results show that miR-34a represents a tumor suppressor gene which is inactivated by CpG methylation and subsequent transcriptional silencing in a broad range of tumors.


Related Papers

No related papers found

Powered by citation graph analysis